Advertisement

Skin Manifestations of Raynaud’s Phenomenon

  • Noëlle S. SherberEmail author
  • Fredrick M. Wigley
Chapter

Abstract

Raynaud’s phenomenon presents clinically as cold mottled skin and most commonly involves the extremities. It results from vasoconstriction of the superficial thermoregulatory vessels as an exaggerated response to cold temperatures and/or to stress. It can occur primarily, without an associated autoimmune disease, or can relate to underlying rheumatic diseases such as scleroderma or mixed connective tissue disease.

Keywords

Carpal Tunnel Syndrome Mixed Connective Tissue Disease Thoracic Outlet Syndrome Digital Artery Undifferentiated Connective Tissue Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    Gelber AC, Wigley FM, Stallings RY, et al. Symptoms of Raynaud’s phenomenon in an inner-city African-American community: prevalence and self-reported cardiovascular comorbidity. J Clin Epidemiol. 1999;52:441–6.PubMedCrossRefGoogle Scholar
  2. 2.
    Block JA, Sequeira W. Raynaud’s phenomenon. Lancet. 2001;357:2042–8.PubMedCrossRefGoogle Scholar
  3. 3.
    Maricq HR, Carpentier PH, Weinrich MC, et al. Geographic variation in the prevalence of Raynaud’s phenomenon: Charleston, SC, USA, vs Tarentaise, Savoie, France. J Rheumatol. 1993;20:70–6.PubMedGoogle Scholar
  4. 4.
    Sharp GC, Irvin WS, May CM, et al. Association of antibodies to ribonucleoprotein and Sm antigens with mixed connective-tissue disease, systematic lupus erythematosus and other rheumatic diseases. N Engl J Med. 1976;295:1149–4.PubMedCrossRefGoogle Scholar
  5. 5.
    Tuffanelli DL, Winkelmann RK. Systemic scleroderma, a clinical study of 727 cases. Arch Dermatol. 1961;84:359–1.PubMedCrossRefGoogle Scholar
  6. 6.
    Parker MD. Ribonucleoprotein antibodies: frequency and clinical significance in systemic lupus erythematosus, scleroderma, and mixed connective tissue disease. J Lab Clin Med. 1973;82:769–5.PubMedGoogle Scholar
  7. 7.
    Cohen ML, Dawkins B, Dawkins RL, et al. Clinical significance of antibodies to ribonucleoprotein. Ann Rheum Dis. 1979;38:74–8.PubMedCrossRefGoogle Scholar
  8. 8.
    De Angelis R, Cerioni A, Del Medico P, et al. Raynaud’s phenomenon in undifferentiated connective tissue disease (UCTD). Clin Rheumatol. 2005;24:145–51.PubMedCrossRefGoogle Scholar
  9. 9.
    Mosca M, Neri R, Bencivelli W, et al. Undifferentiated connective tissue disease: analysis of 83 patients with a minimum followup of 5 years. J Rheumatol. 2002;29:2345–9.PubMedGoogle Scholar
  10. 10.
    Estes D, Christian CL. The natural history of systemic lupus erythematosus by prospective analysis. Medicine (Baltimore). 1971;50:85–95.Google Scholar
  11. 11.
    Hochberg MC, Boyd RE, Ahearn JM, et al. Systemic lupus erythematosus: a review of clinico-laboratory features and immunogenetic markers in 150 patients with emphasis on demographic subsets. Medicine (Baltimore). 1985;64:285–95.Google Scholar
  12. 12.
    Saraux A, Allain J, Guedes C, et al. Raynaud’s phenomenon in rheumatoid arthritis. Br J Rheumatol. 1996;35:752–4.PubMedCrossRefGoogle Scholar

Suggested Readings

  1. Boin F, Wigley FM. Understanding, assessing and treating Raynaud’s phenomenon. Curr Opin Rheumatol. 2005;17:752–60.PubMedGoogle Scholar
  2. Flavahan NA. Regulation of vascular activity in scleroderma: new insights into Raynaud’s phenomenon. Rheum Dis Clin North Am. 2008;34(1):81–7; vii.Google Scholar
  3. Generini S, Seibold JR, Matucci-Cerinic M. Estrogens and neuropeptides in Raynaud’s phenomenon. Rheum Dis Clin North Am. 2005; 31:177–86, x–xi.Google Scholar
  4. Henness S, Wigley FM. Current drug therapy for scleroderma and secondary Raynaud’s phenomenon. Curr Opin Rheumatol. 2007;19(6):611–8.PubMedCrossRefGoogle Scholar
  5. Herrick AL. Pathogenesis of Raynaud’s phenomenon. Rheumatology. 2005;44:587–96.PubMedCrossRefGoogle Scholar
  6. Herrick AL. Therapy: a local approach to Raynaud phenomenon. Nat Rev Rheumatol. 2009;5:246–7.PubMedCrossRefGoogle Scholar
  7. Malenfant D, Catton M, Pope JE. The efficacy of complementary and alternative medicine in the treatment of Raynaud’s phenomenon: a literature review and meta-analysis. Rheumatology (Oxford). 2009;48:791–5.CrossRefGoogle Scholar
  8. Steen V, Denton CP, Pope JE, Matucci-Cerinic M. Digital ulcers: overt vascular disease in scleroderma. Rheumatology (Oxford). 2009;48 Suppl 3:iii19–24.CrossRefGoogle Scholar
  9. Thompson AE, Pope JE. Calcium channel blockers for primary Raynaud’s phenomenon: a meta-analysis. Rheumatology (Oxford). 2005;44:145–50.CrossRefGoogle Scholar
  10. Wigley FM. Raynaud’s phenomenon. N Eng J Med. 2002;347:1001–8.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2014

Authors and Affiliations

  1. 1.Johns Hopkins Scleroderma CenterBaltimoreUSA
  2. 2.Division of RheumatologyJohns Hopkins University School of MedicineBaltimoreUSA

Personalised recommendations